key: cord-0897293-dvp7kdyc authors: Nishimura, Naoya; Shiomichi, Yasuko; Takeuchi, Satoshi; Akamine, Shun; Yoneda, Reiko; Yoshizawa, Seiji title: IgA Vasculitis Following COVID-19 Vaccination date: 2022-03-04 journal: Mod Rheumatol Case Rep DOI: 10.1093/mrcr/rxac014 sha: de8ea18466842c2e515556f28bb03f3e111b3783 doc_id: 897293 cord_uid: dvp7kdyc IgA vasculitis is generally triggered by infectious causes, but it has also been reported after immunization with various vaccines. Herein, we report two cases of IgA vasculitis after receiving the first or second dose of the Pfizer-BioNTech BNT16B2b2 mRNA vaccine. Two men, aged 22 and 30 years, developed palpable purpura on the extremities and arthritis. One patient also complained of fever and gastrointestinal symptoms. Laboratory findings revealed mild leukocytosis and slightly elevated C-reactive protein level, although platelet count and coagulation profile were within normal levels in both cases. Proteinuria and microhematuria were seen in one patient. Skin biopsies were performed in both patients and revealed leukocytoclastic vasculitis. The deposit of IgA and C3 was shown on immunofluorescence studies in one patient. Both patients were diagnosed with IgA vasculitis and treated with prednisolone, and their symptoms resolved within 1 week after initiation of treatment. The COVID-19 mRNA vaccine could trigger IgA vasculitis; however, a coincidence cannot be ruled out. IgA vasculitis, previously also known as Henoch-Schönlein purpura, is an immune-mediated systemic small-vessel vasculitis characterized as cutaneous palpable purpura, arthritis, abdominal pain, and renal disease. It occurs primarily in childhood and in most cases is self-limited. Although adult cases of IgA vasculitis are less common, adults have significantly worse renal outcomes than children do. The exact etiology of IgA vasculitis is still unknown but seems to be related to genetic, environmental, and infectious causes. One-half of IgA vasculitis cases are preceded by upper respiratory tract infection, which possibly explains the association between IgA vasculitis and infection. In addition, cases of IgA vasculitis have been reported to be presented following immunization with various vaccines, suggesting that vaccines also could trigger IgA vasculitis. Herein, we report two cases of IgA vasculitis following the COVID-19 mRNA vaccination. A 30-year-old Japanese man was admitted to our hospital with a rash on the extremities, fever, abdominal pain, and arthralgia. Five days before admission, he received a second dose of the Pfizer-BioNTech BNT16B2b2 mRNA vaccine. He complained of mild fatigue and myalgia after the first and second vaccination doses, but these symptoms were resolved within a few days. The patient was not taking any new medications and showed no signs of infection, including COVID-19, before admission. Physical examination revealed palpable purpura on the extremities and trunk (Figure 1 ), fever, abdominal pain, and swelling of the left knee. Laboratory findings indicated a white blood cell (WBC) count of 11,200/µL (normal, <8,600/µL), with neutrophils accounting for 90%, and C-reactive protein (CRP) of 1.18 mg/dL (normal, <0.15 mg/dL), IgA of 307 mg/dL (normal, 93-393 mg/dL). Microhematuria of 30-49/HPF and mild proteinuria of 0.20 g/g of creatinine was also observed. Hemoglobin, platelet count, liver enzymes, renal function, and coagulation tests were within normal limits. Antinuclear antibody was positive with a low titer, and myeloperoxidase antineutrophil cytoplasmic antibody (ANCA) and proteinase-3 ANCA were negative. Skin biopsy of the lesion on the left forearm revealed erosion in the epidermis with neutrophilic infiltration, extravasation of red blood cells (RBCs), nuclear debris in the perivascular area, and fibrin deposit, all of which were consistent with leukocytoclastic vasculitis (Figure 2 (1, 2) , and the diagnosis of IgA vasculitis was made. He was treated with intravenous prednisolone (PSL) 60 mg daily for 3 days, followed by oral PSL 40 mg daily. His symptoms were improved within 1 week after treatment began, except for hematuria and proteinuria. Although abnormalities in urinalysis persisted, they improved after 1 month. PSL was gradually tapered, as there was no exacerbation of IgA vasculitis. A 22-year-old Japanese man was admitted to our hospital with a rash on the lower limbs and arthralgia. He had a history of recurring tonsillitis. He received the first dose of the Phizer-BioNTech BNT16B2b2 vaccine 6 days before onset without any symptoms after the vaccination. He was not taking any new medications but complained of discomfort in the throat before onset. Although he visited a dermatologist for a skin rash on the lower limbs and was prescribed medication, the rash was spread and the pain of the left knee also appeared, then he was consulted to our hospital. Physical examination revealed palpable purpura on the lower limbs ( Figure 4 ), swelling of the left knee, and only mild swelling of the tonsils. He did not complain of fever or gastrointestinal symptoms. Laboratory findings indicated a WBC count of 10,000/µL (normal, <8,600/µL), with neutrophils accounting for 81%, and CRP of 0.27 mg/dL (normal, <0.15 mg/dL). IgA was not measured. Hemoglobin, platelet count, liver enzymes, renal function, urinalysis, and coagulation tests were within normal limits. Anti-streptolysin O antibody (ASO) was 72 IU/mL (normal, <239 IU/mL) and anti-streptokinase antibody (ASK) was x320 (normal,